David‐Alexandre Gross

Author

Also Known As

D Gross, D-A Gross, D. A. Gross, D. Gross, D.A. Gross, David A Gross, David A. Gross, David Alexandre Gross, David Gross, David-Alexandre Gross

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Inserm Genethon (France)Centre National de la Recherche Scientifique Institut Pasteur Institut Gustave Roussy

About

David‐Alexandre Gross is an author at Inserm specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	828
2	Immunology	12	12	810
3	Cell Biology	11	11	797
4	Health Sciences	1	1	18
5	Nephrology	1	1	18

David‐Alexandre Gross

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes Sophie Tourdot, Antonio Scardino, Eleanna Saloustrou, European Journal of Immunology HlaHistocompatibilityGeneral StrategyHla ImmunogeneticsImmunology	2000	125
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy David‐Alexandre Gross, Stéphanie Graff‐Dubois, Paule Opolon, Journal of Clinical Investigation ImmunologyImmunotherapyTumor BiologyTumor ImmunologyVaccine Target	2004	122
HER-2/ <i>neu</i> and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy Antonio Scardino, David‐Alexandre Gross, Pedro M. Sousa Alves, The Journal of Immunology	2002	121
A lentiviral vector encoding the human Wiskott–Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice Sabine Charrier, Daniel Stockholm, Khalil Seye, Gene Therapy ImmunogeneticsCytoskeletal DefectsImmune Cell DevelopmentImmunodeficienciesPathogenesis	2004	109
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy David‐Alexandre Gross, Stéphanie Graff‐Dubois, Paule Opolon, Journal of Clinical Investigation ImmunologyImmunotherapyTumor BiologyTumor ImmunologyVaccine Target	2004	109
Foxp3 <sup>+</sup> CD25 <sup>+</sup> regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage Julie Cabarrocas, Cécile Cassan, Fay Magnusson, Proceedings of the National Academy of Sciences Lymphocyte DevelopmentT-regulatory CellImmune RegulationImmunologyRegulatory T Cells	2006	93
Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node Ruby Alonso, Héloïse Flament, Sébastien Lemoine, Nature Communications	2018	91
STEAP, a prostate tumor antigen, is a target of human CD8+ T cells Pedro M. Sousa Alves, Olivier Faure, Stéphanie Graff‐Dubois, Cancer Immunology Immunotherapy Cancer ImmunosurveillanceImmunologyPathologyAntigen ProcessingProstatic Disease	2006	75
Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy Stéphanie Graff‐Dubois, Olivier Faure, David‐Alexandre Gross, The Journal of Immunology	2002	74
EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Pedro M. Sousa Alves, Olivier Faure, Stéphanie Graff‐Dubois, PubMed Tumor BiologyCancer ImmunosurveillanceImmunologyTumor ImmunityPathology	2003	56

Page 1